Novel Recurrence Risk Stratification of Resected Pancreatic Neuroendocrine Tumor

Radical surgical resection represents the only hope of cure for pancreatic neuroendocrine tumor (PanNET). Adjuvant therapy is rarely used because there is no evidence to distinguish patients with high recurrence risk. Here weinvestigated the recurrence feature ofresected PanNET and established a novel risk stratification to predict its recurrence. We analyzed 505 PanNET patients who underwent R0 resectionat our institute from January 2004 through May 2015. The median follow-up was 71months (range: 12months to 143months), 129 patients (25.5%) experienced recurrence with median disease-free survival (mDFS) of 19months.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2yVu8pt
via IFTTT